This article has been updated with comments from Cepheid's CEO, John Bishop.

NEW YORK (GenomeWeb) – Cepheid reported after the close of the market on Tuesday that its fourth-quarter revenues rose 12 percent year-over-year, and attributed the growth to what it called record reagent revenues and GeneXpert system placements.

The Sunnyvale, Calif.-based firm reported revenues of $147.0 million for the three months ended Dec. 31, 2015, up from $131.5 million in Q4 2014 and in line with the consensus analyst estimate of $146.9 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Mary Beckerle has been removed as director of the Huntsman Cancer Institute in what one researcher refers to as a "coup," ScienceInsider reports.

Bill Gates tells the Telegraph that bioterrorism is a serious risk.

The March for Science is to take place tomorrow, and supporters are tapping their creative energies to create placards to carry.

CBS News reports that the White House Science Fair is to continue under President Donald Trump.